Skip to main content

Table 3 Changes in signs and symptoms of psoriasis between baseline and week 24

From: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

 BaselineWeek 24p value
Characteristic (n = 18)
 PASI (median, IQR)6.9 (3.5, 18.6)0.4 (0, 1.5)0.002**
 BSA% (median, IQR)10.9 (3.6, 20.3)0.2 (0, 1.8)0.003**
 DLQI (median, IQR)10 (5, 15)1.5 (0.75, 5.75)0.003**
 VAS pain (median, IQR)18.5 (11.75, 49.5)7 (1, 14)0.003**
 VAS global (median, IQR)68 (45, 74)8 (2.5, 26)< 0.001**
 VAS physician (median, IQR)35.5 (8.75, 62.75)7 (1, 15)0.011*
 TJC 78 (median, IQR) (mean ± SD)0 (0, 3.75); 2.65 ± 5.110 (0, 2); 0.63 ± 1.170.102
 PsAID (median, IQR)3.5 (1.65, 1.7)1.35 (0.2, 2.35)0.003**
Characteristic (n = 15)
 PASI (median, IQR)6.9 (3.3, 15.4)0.3 (0, 1.1)0.007**
 BSA% (median, IQR)9.2 (4.3, 18.1)0.05 (0, 1)0.013*
 DLQI (median, IQR)12 (6.75, 15.75)2 (0.75, 8.25)0.013*
 VAS pain (median, IQR)26 (14, 50)4 (1, 23)0.004**
 VAS global (median, IQR)70 (61, 75)12 (1, 38)0.001**
 VAS physician (median, IQR)37 (7, 50)4 (1, 22)0.036*
 TJC 78 (median, IQR) (mean ± SD)1 (0, 4); 3.53 ± 5.670 (0, 2); 0.53 ± 0.920.038*
 PsAID (median, IQR)3.7 (2.84, 6.01)1.45 (0.25, 3.2)0.005**
  1. Data on the upper half are based on 18 psoriasis patients with complete baseline and 24-week data. Data on the lower half are based on patients with active joint inflammation in MRI at baseline (n = 15)
  2. TJC tender joint count, VAS visual analogue scale, PASI psoriasis area and severity index, BSA% percent body surface area, IQR interquartile range, DLQI dermatology life quality index, PsAID psoriatic arthritis impact of disease
  3. Additionally reported as mean and standard deviation (mean ± SD) because median was equal to zero
  4. Wilcoxon signed-rank test. *p ≤ 0.05, **p ≤ 0.01